Related Experiment Video

Updated: May 20, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

Circulating microparticles in carriers of factor V Leiden with and without a history of venous thrombosis

Elena Campello1, Luca Spiezia, Claudia M Radu

  • 1Department of Cardiologic, Thoracic, and Vascular Sciences, 2nd Chair of Internal Medicine, University of Padua Medical School, Padua, Italy.

Thrombosis and Haemostasis
|July 28, 2012
PubMed

Insights

Elevated levels of circulating microparticles (MP) are linked to increased thrombotic risk in Factor V Leiden (FVL) carriers. These findings suggest microparticles may play a role in venous thromboembolic (VTE) events for FVL mutation carriers.

Area of Science:

  • Hematology
  • Vascular Biology
  • Genetics

Background:

  • Factor V Leiden (FVL) mutation is a known risk factor for venous thromboembolism (VTE).
  • The precise mechanisms underlying why only a subset of FVL carriers develop VTE remain unclear.
  • Circulating microparticles (MP) are increasingly recognized for their role in hemostasis and thrombosis.

Purpose of the Study:

  • To investigate the association between circulating microparticle levels and thrombotic risk in Factor V Leiden carriers.
  • To compare MP levels and procoagulant activity between FVL carriers and healthy controls.
  • To explore differences in MP levels based on FVL mutation status (homozygous vs. heterozygous) and VTE history.

Main Methods:

  • Plasma levels of various microparticle subtypes (annexin V-MP, platelet-MP, endothelial-MP, leukocyte-MP, TF(+)MP) were quantified.
  • Microparticle procoagulant activity (PPL) was measured.
  • The study included 142 FVL carriers (30 homozygous, 49 with prior VTE) and 142 matched healthy controls.

Main Results:

  • FVL carriers exhibited significantly higher levels of annexin V-MP compared to controls (p<0.0001).
  • Significant differences in platelet-MP, endothelial-MP, and leukocyte-MP levels were observed between homozygous and heterozygous FVL carriers.
  • Elevated annexin V-MP levels and increased MP procoagulant activity were associated with a history of VTE in FVL carriers (p<0.005).

Conclusions:

  • Circulating microparticle levels are elevated in Factor V Leiden carriers.
  • Specific microparticle subtypes and their procoagulant activity correlate with thrombotic risk in FVL mutation carriers.
  • These findings suggest that microparticles may contribute to the pathogenesis of venous thromboembolism in FVL carriers.

More Related Videos

Determination of the Procoagulant Activity of Extracellular Vesicle (EV) Using EV-Activated Clotting Time (EV-ACT)04:56

Determination of the Procoagulant Activity of Extracellular Vesicle (EV) Using EV-Activated Clotting Time (EV-ACT)

Published on: August 4, 2023

Routine Screening Method for Microparticles in Platelet Transfusions09:49

Routine Screening Method for Microparticles in Platelet Transfusions

Published on: January 31, 2018

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.